1 |
Barnig C, Frossard N, Levy BD. Towards targeting resolution pathways of airway inflammation in asthma [J]. Pharmacol Ther, 2018, 186: 98-113.
|
2 |
Lambrecht BN, Hammad H. The immunology of asthma [J]. Nat Immunol, 2015, 16: 45-56.
|
3 |
Johansson K, McSorley HJ. IL-33 in the developing lung-roles in asthma and infection [J]. Pediatr Allergy Immunol, 2019, 30(5): 503-510.
|
4 |
Baekkevold ES, Roussigne M, Yamanaka T, et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules [J]. Am J Pathol, 2003, 163: 69-79.
|
5 |
Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines [J]. Immunity, 2005, 23: 479-490.
|
6 |
Luthi AU, Cullen SP, McNeela EA, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases [J]. Immunity, 2009, 31: 84-98.
|
7 |
Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo [J]. Proc Natl Acad Sci U S A, 2007, 104: 282-287.
|
8 |
Dunne A, O′Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense [J]. Sci STKE, 2003, 2003(171): re3.
|
9 |
Klemenz R, Hoffmann S, Werenskiold AK. Serum- and oncoprotein-mediated induction of a gene with sequence similarity to the gene encoding carcinoembryonic antigen [J]. Proc Natl Acad Sci U S A, 198, 86: 5708-5712.
|
10 |
Pecaric-Petkovic T, Didichenko SA, Kaempfer S, et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33 [J]. Blood, 2009, 113: 1526-1534.
|
11 |
Neill DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity [J]. Nature, 2010, 464: 1367-1370.
|
12 |
Rossler U, Thomassen E, Hultner L, et al. Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo [J]. Dev Biol, 11995, 168: 86-97.
|
13 |
Liang Y, Yang N, Pan G, et al. Elevated IL-33 promotes expression of MMP2 and MMP9 via activating STAT3 in alveolar macrophages during LPS-induced acute lung injury [J]. Cell Mol Biol Lett, 2018, 23: 52.
|
14 |
Zhang L, Jiang LL, Cao ZW. Interleukin-33 promotes the inflammatory reaction in chronic rhinosinusitis with nasal polyps by NF-kappaB signaling pathway [J]. Eur Rev Med Pharmacol Sci, 2017, 21: 4501-4508.
|
15 |
Zhang Y, Bian C, Wu J, et al. IL-33 promotes airway remodeling in a mouse model of asthma via ERK1/2 signaling pathway [J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2016, 32: 590-594.
|
16 |
Ashlin TG, Buckley ML, Salter RC, et al. The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways [J]. Int J Biochem Cell Biol, 2014, 46: 113-123.
|
17 |
Tashiro H, Takahashi K, Hayashi S, et al. Interleukin-33 from Monocytes Recruited to the Lung Contributes to House Dust Mite-Induced Airway Inflammation in a Mouse Model [J]. PLoS One, 2016, 11: e0157571.
|
18 |
Yagami A, Orihara K, Morita H, et al. IL-33 mediates inflammatory responses in human lung tissue cells [J]. J Immunol, 2010, 185: 5743-5750.
|
19 |
Bunting MM, Shadie AM, Flesher RP, et al. Interleukin-33 drives activation of alveolar macrophages and airway inflammation in a mouse model of acute exacerbation of chronic asthma [J]. Biomed Res Int, 2013, 2013: 250938.
|
20 |
Kondo Y, Yoshimoto T, Yasuda K, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system [J]. Int Immunol, 2008, 20: 791-800.
|
21 |
Sjoberg LC, Nilsson AZ, Lei Y, et al. Interleukin 33 exacerbates antigen driven airway hyperresponsiveness, inflammation and remodeling in a mouse model of asthma [J]. Sci Rep, 2017, 7: 4219.
|
22 |
Zhiguang X, Wei C, Steven R, et al. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice [J]. Immunol Lett, 2010, 131: 159-165.
|
23 |
Han H, Ziegler SF. Intradermal administration of IL-33 induces allergic airway inflammation [J]. Sci Rep, 2017, 7: 1706.
|
24 |
Lei Y, Boinapally V, Zoltowska A, et al. Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma [J]. PLoS One, 2015, 10: e0133774.
|
25 |
Shadie AM, Herbert C, Kumar RK. Ambient particulate matter induces an exacerbation of airway inflammation in experimental asthma: role of interleukin-33 [J]. Clin Exp Immunol, 2014, 177: 491-499.
|
26 |
Mathews JA, Krishnamoorthy N, Kasahara DI, et al. IL-33 Drives Augmented Responses to Ozone in Obese Mice [J]. Environ Health Perspect, 2017, 125: 246-253.
|
27 |
Zoltowska AM, Lei Y, Fuchs B, et al. The interleukin-33 receptor ST2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma [J]. Clin Exp Allergy, 2016, 46: 479-490.
|
28 |
Oboki K, Ohno T, Kajiwara N, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity [J]. Proc Natl Acad Sci U S A, 2010, 107: 18581-18586.
|
29 |
Louten J, Rankin AL, Li Y, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation [J]. Int Immunol, 2011, 23: 307-315.
|
30 |
Kaur D, Gomez E, Doe C, et al. IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: airway smooth muscle crosstalk [J]. Allergy, 2015, 70: 556-567.
|
31 |
Guo Z, Wu J, Zhao J, et al. IL-33/ST2 promotes airway remodeling in asthma by activating the expression of fibronectin 1 and type 1 collagen in human lung fibroblasts [J]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2014, 30: 975-979.
|
32 |
Ravanetti L, Dijkhuis A, Dekker T, et al. IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity [J]. J Allergy Clin Immunol, 2019, 143(4): 1355-1370.e16.
|
33 |
Werder RB, Zhang V, Lynch JP, et al. Chronic IL-33 expression predisposes to virus-induced asthma exacerbations by increasing type 2 inflammation and dampening antiviral immunity [J]. J Allergy Clin Immunol, 2018, 141(5): 1607-1619.e9.
|
34 |
Ito R, Maruoka S, Soda K, et al. A humanized mouse model to study asthmatic airway inflammation via the human IL-33/IL-13 axis [J]. JCI Insight, 2018, 3(21).pii:121580.
|
35 |
Li J, Zhang L, Chen X, et al. Pollen/TLR4 innate immunity signaling initiates IL-33/ST2/Th2 pathways in allergic inflammation [J]. Sci Rep, 2016, 6: 36150.
|